Literature DB >> 26701615

Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4.

Xiaobin Feng1, Lifen Zhao1, Shuhang Gao2, Xiaobo Song3, Weijie Dong4, Yongfu Zhao5, Huimin Zhou6, Lei Cheng7, Xiaolong Miao5, Li Jia8.   

Abstract

Fucosylation is the final step in the glycosylation machinery, which produces glycans involved in tumor multidrug resistance development. MicroRNAs (miRNAs) are endogenous negative regulators of gene expression and have been implicated in most cellular processes of tumors, including drug resistance. This study was undertaken to determine the roles of fucosylation and miR-224-3p in multidrug resistance of human breast cancer cell lines. Comparative analysis revealed differential modification patterns of fucosylation of the fucosylated N-glycans in drug-resistant T47D/ADR cells and sensitive line T47D cells. The expressional profiles of fucosyltransferase genes in two pairs of parental and chemoresistant human breast cancer cell lines showed that FUT4 was up-regulated highly in MDR cell lines. Altered level of FUT4 affected the drug-resistant phenotype of T47D and T47D/ADR cells both in vitro and in vivo. By bioinformatics analysis, we identified FUT4 as one of the miR-224-3p-targeted genes. Further studies showed an inverse relationship between of FUT4 and miR-224-3p in parental and ADR-resistant breast cancer cells, wherein miR-224-3p was downregulated in resistant cells. 3'-UTR dual-luciferase reporter assay confirmed that miR-224-3p directly targeted 3'-untranslation region (3'-UTR) of FUT4 mRNA. In addition, miR-224-3p overexpression sensitized T47D/ADR cells to chemotherapeutics and reduced the growth rate of breast cancer xenografts in vivo. Our results indicate that FUT4 and miR-224-3p are crucial regulators of cancer response to chemotherapy, and may serve as therapeutic targets to reverse chemotherapy resistance in breast cancer.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Fucosylated N-glycan; Fucosyltransferase; Human breast cancer cell lines; Multidrug resistance; miR-224-3p

Mesh:

Substances:

Year:  2015        PMID: 26701615     DOI: 10.1016/j.gene.2015.12.028

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  24 in total

1.  A fucosyltransferase inhibition assay using image-analysis and digital microfluidics.

Authors:  Laura M Y Leclerc; Guy Soffer; David H Kwan; Steve C C Shih
Journal:  Biomicrofluidics       Date:  2019-05-10       Impact factor: 2.800

Review 2.  Exosomes-mediate microRNAs transfer in breast cancer chemoresistance regulation.

Authors:  Juliana Carvalho Santos; Marcelo Lima Ribeiro; Luis Otávio Sarian; Manoela Marques Ortega; Sophie Françoise Derchain
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

3.  LncRNA SNHG4 promotes tumour growth by sponging miR-224-3p and predicts poor survival and recurrence in human osteosarcoma.

Authors:  Ruida Xu; Fan Feng; Xiaosheng Yu; Zude Liu; Lifeng Lao
Journal:  Cell Prolif       Date:  2018-08-28       Impact factor: 6.831

4.  MiR-202-5p/PTEN mediates doxorubicin-resistance of breast cancer cells via PI3K/Akt signaling pathway.

Authors:  Tao Liu; Jichao Guo; Xiaoxia Zhang
Journal:  Cancer Biol Ther       Date:  2019-04-14       Impact factor: 4.742

5.  LC-MS/MS isomeric profiling of permethylated N-glycans derived from serum haptoglobin of hepatocellular carcinoma (HCC) and cirrhotic patients.

Authors:  Yifan Huang; Shiyue Zhou; Jianhui Zhu; David M Lubman; Yehia Mechref
Journal:  Electrophoresis       Date:  2017-07-14       Impact factor: 3.535

6.  FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma.

Authors:  Chang Liu; Zhi Li; Shuo Wang; Yibo Fan; Simeng Zhang; Xianghong Yang; Kezuo Hou; Jianhua Tong; Xuejun Hu; Xiaonan Shi; Xiaoxun Wang; Yunpeng Liu; Xiaofang Che; Xiujuan Qu
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-24       Impact factor: 4.553

7.  Functional roles of sialylation in breast cancer progression through miR-26a/26b targeting ST8SIA4.

Authors:  Xiaolu Ma; Weijie Dong; Zhen Su; Lifen Zhao; Yuan Miao; Nana Li; Huimin Zhou; Li Jia
Journal:  Cell Death Dis       Date:  2016-12-29       Impact factor: 8.469

8.  microRNA Expression in Ethnic Specific Early Stage Breast Cancer: an Integration and Comparative Analysis.

Authors:  Farah J Nassar; Rabih Talhouk; Nathalie K Zgheib; Arafat Tfayli; Maya El Sabban; Nagi S El Saghir; Fouad Boulos; Mark N Jabbour; Claude Chalala; Rose-Mary Boustany; Humam Kadara; Zhou Zhang; Yinan Zheng; Brian Joyce; Lifang Hou; Ali Bazarbachi; George Calin; Rihab Nasr
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

9.  MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway.

Authors:  Yuan Miao; Wei Zheng; Nana Li; Zhen Su; Lifen Zhao; Huimin Zhou; Li Jia
Journal:  Sci Rep       Date:  2017-02-06       Impact factor: 4.379

Review 10.  Glycosylation in Cancer: Interplay between Multidrug Resistance and Epithelial-to-Mesenchymal Transition?

Authors:  Leonardo Marques da Fonseca; Vanessa Amil da Silva; Leonardo Freire-de-Lima; José Osvaldo Previato; Lucia Mendonça-Previato; Márcia Alves Marques Capella
Journal:  Front Oncol       Date:  2016-06-22       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.